Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 15, 2015.
Article Versions
- You are currently viewing a previous version of this article (January 15, 2015 - 08:49).
- View the most recent version of this article
Copyright & Usage
Copyright © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Ezgi Ilan1,
- Mattias Sandström,
- Cecilia Wassberg,
- Anders Sundin,
- Ulrike Garske-Román,
- Barbro Eriksson,
- Dan Granberg and
- Mark Lubberink
- ↵ For correspondence or reprints contact: Ezgi Ilan, Uppsala University Hospital, Section of Medical Physics, SE-751 85 Uppsala, Sweden. E-mail: ezgi.ilan@akademiska.se
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy
- Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
- Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
- Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
- The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy
- Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
- A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients
- Variability and Repeatability of Quantitative Uptake Metrics in 18F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol
- Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
- Molecular radiotheranostics for neuroendocrine tumours
- Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
- Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
- Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting
- MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy